Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Nexien BioPharma's annualizedGross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil.
Nexien BioPharma's average Total Assets over the quarter that ended in Mar. 2024 was $0.01 Mil. Therefore, Nexien BioPharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.
Nexien BioPharma Gross-Profit-to-Asset % Historical Data
The historical data trend for Nexien BioPharma's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nexien BioPharma's Gross-Profit-to-Asset %
For the Drug Manufacturers - Specialty & Generic subindustry, Nexien BioPharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexien BioPharma's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nexien BioPharma's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Nexien BioPharma's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Nexien BioPharma Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Nexien BioPharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Nexien BioPharma (Nexien BioPharma) Business Description
Nexien BioPharma Inc is a researcher and developer of cannabinoid-based pharmaceutical for various medical conditions and disorders, all under U.S. Food and Drug Administration development pathways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NXEN has been successfully added to your 